Patent ID: 9433604
Filing Date: 2016-09-06
CPC Classification: A61K,A61P

Claim Text:
1. A method of inhibiting the growth of cancerous cells that contain an enhanced amount of one or more of phosphorylated-mTOR, phosphorylated-Akt1, phosphorylated-ERK2 and serine2152-phosphorylated filamin A that comprises contacting said cancer cells with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds in a solid phase assay to the pentapeptide of FLNA of SEQ ID NO: 1, said compound or salt exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 μM concentration, using unlabeled naloxone as the control inhibitor at the same concentration as said compound or salt, said pentapeptide of FLNA being biotinylated at its N-terminal valine residue and bound to a streptavidin-coated solid support, wherein said enhanced amount of phosphorylated-mTOR, phosphorylated-Akt1, phosphorylated-ERK2 and serine2152-phosphorylated filamin A being an amount that is significantly greater than the amount present in a non-cancerous cell of the same type, wherein said compound is a compound of Series C-2 that corresponds in structure to the Formula I below: wherein J and F are the same or different and are CH Q is CHR each of m, n and p is zero or one and the sum of m+n+p is 2; W is selected from the group consisting of NR X is SO circle A is an aromatic or heteroaromatic ring system that contains a single ring or two fused rings; R wherein the amido nitrogen in either amide group has the formula NR MAr, where M is —CH 2 —, —O— or —N═N— and Ar is a single-ringed aryl or heteroaryl group and NR 5 R 6 wherein R 5 and R 6 are the same or different and are H, C 1 -C 4 hydrocarbyl, C 1 -C 4 acyl, C 1 -C 4 hydrocarbylsulfonyl, or R 5 and R 6 together with the nitrogen form a 5-7-membered ring that optionally contains 1 or 2 additional hetero atoms that independently are nitrogen, oxygen or sulfur; and R